Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about RNAZ, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Evorpacept (ALX148) | HER2-positive Breast Cancer | Phase 1/2 · NCT05868226 | Recruiting |
| MicroRNA-10b Antagomir-Iron Oxide/Dextra | Advanced Solid Tumor | Phase 1/2 · NCT06260774 | Active not recruiting |
| Copper Cu 64 NODAGA-TTX-MC138 | Advanced Solid Tumor | Early Phase 1 · NCT05908773 | Completed |
Also used in these trials (approved or third-party drugs, not RNAZ's own candidates): Fam-Trastuzumab Deruxtecan-Nxki, Tucatinib, Zanidatamab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
RNAZ holds $8.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $5.2M/quarter from operations, an estimated runway of 4.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 55 · Elevated
Due to the Company’s recurring and expected continuing losses from operations, the Company has concluded there is substantial doubt concerning its ability to continue as a going concern for one year after the issuance of these consolidated financial statements without additional capital becoming available.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RNAZ files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RNAZ and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →